Drug intelligence / Profile preview

myrtenal

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Intraperitoneal, Intravenous
01

Overview

Myrtenal is a bicyclic monoterpenoid, naturally present in the essential oils of diverse plants, including *Myrtus communis*, rosemary, spearmint, peppermint, mandarin peel, and more. It is a small molecule characterized by the formula C10H14O. While not an approved pharmaceutical, studies report diverse experimental biological activities including antihyperglycemic, antioxidant, antitumor, analgesic, anti-inflammatory, neuroprotective, vasodilatory, and antibacterial effects. Myrtenal acts through multiple mechanisms, including modulation of glucose metabolism, antioxidant activity, regulation of neurotransmitters, inhibition of V-type ATPase on tumor cells, anti-inflammatory activity (through suppression of IL-1β, TNF-α, and NLRP3 inflammasome), and influencing monoamines in the CNS. It is investigated mostly in preclinical settings in animal models for diabetes, cancer, neurodegenerative disorders (Parkinson’s disease, dementia), and as an analgesic and anti-inflammatory agent. Myrtenal is also a minor component in some foods and a precursor in pinene metabolism in plants[1][3].

Other names
myrtenal(-)-myrtenall-myrtenal(?)-myrtenal(1R)-(-)-myrtenal6,6-dimethylbicyclo[3.1.1]hept-2-ene-2-carbaldehydebicyclo[3.1.1]hept-2-ene-2-carboxaldehydeFEMA 3395FEMA3395FEMA-3395
02

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)V-ATPase (Vacuolar-type H+-ATPase)

Beyond the preview

Go deeper on myrtenal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on myrtenal.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call